21st Jun 2018 11:07
LONDON (Alliance News) - Silence Therapeutics PLC said Thursday it appointed Dave Lemus to the board as non-executive director effective immediately.
The company focused on the discovery and development of treatment options for diseases with unmet medical need, also appointed Richard Jenkins as head of Clinical Development.
Lemus currently holds three roles at at Proteros Biostructures GmbH, executive vice chair, chief operating officer and chief financial officer.
He is also non-executive director at BioHealth Innovation Inc, and Sorrento Therapeutics Inc.
Jenkins will be heading the clinical development function as Silence Therapeutics advances its lead asset through the clinic, reporting directly to Executive Chair Annalisa Jenkins, the company said.
He was senior scientific director at Takeda Development Centre Europe Ltd and worked for GlaxoSmithKline Pharmaceuticals PLC.
Silence Therapeutics shares were trading flat at 144.00 pence.
Related Shares:
SLN.LGlaxosmithkline